NOVOCURE LTD WKN: A140ML ISIN: JE00BYSS4X48 Kürzel: NVCR Forum: Aktien Thema: Hauptdiskussion

Reuters Novocure jumps on FDA approval for lung cancer treatment Oct 16, 2024 at 9:31 am GMT ** Shares of cancer therapy developer Novocure NVCR.O rise 33% to $23.65 before the bell ** U.S. Food and Drug Administration approves company's portable device, Optune Lua, in combination with either chemotherapy or immunotherapy, for patients with a type of lung cancer ** NVCR's Optune Lua delivers so-called tumor treating fields therapy that uses low-energy electrical fields to prevent cancer cells from growing and dividing ** Approval is based on results of a late-stage study, in which treatment with Optune Lua helped extend the average time patients lived without their disease progressing by 13.2 months vs 9.9 months for patients who received only chemotherapy or a type of cancer immunotherapy ** As of last close, NVCR up about 19% YTD Reporting by Bhanvi Satija in Bengaluru